HCO 3ATI Pharmacology Proctored 2.
HCO 3ATI
Pharmacology
Proctored 2.
ATI Pharmacology
IMPORTANT LAB VALUES
• Sodium (Na): 136-145 mEq/L
• Calcium: 9.0-10 mg/dL
• Chloride: 98-106 mEq/L
• Bicarb HCO3: 21-28 mEq/L
• Potassium: 3.5-5.0 mg/L
• Phosphorus PO 4 : 3.0-4.5 mg/dL
• Magnesium: 1.3- 2.1 mEq/L
• Cholesterol:
o Total <200mg/dL
o LDL ("bad") <100
o HDL ("good) >40
o Triglycerides <150mg/dL
• Liver enzymes
o ALT/SGPT 8-20 units/L
o AST/SGOT 5-40 units/L
o ALP 42-128 units/L
o Total protein 6-8 gm/dL
• Pancreatic enzymes
o Amylase 56-90 IU/L
o Lipase 0-110 units/L
o Prothrombin time 0.8-1.2
• Glucose:
Preprandial (fasting) 70-110 mg/dL
Postprandial 70-140 mg/dL
• RBC: Females 4.2-5.4 million/uL; Males 4.7-6.1 million /uL
• WBC: 5000 -10,000
• Iron: Females 60-160 mcg/dL; Males 80-180 mcg/dL
• Platelets: 150,000-450,000
• Hemoglobin (Hgb): Females 12-16 g/dL; Males 14-18 g/dL
• Hematocrit (Hct): Females 37-47%;Males 42-52%
• Prothrombin Time (PT): 11-14 seconds: therapeutic range 1.5-2x normal or control
value
• Urine specific gravity: 1.015-1.030
• Urine pH: average 6.0; range 4.6-8.0
• BUN: 10-20 mg/dL
• Creatinine: female 0.5-1.1, males 0.6 - 1.2 mg/dL;
,HCO 3ATI Pharmacology Proctored 2.
• Creatinine phosphokinase MB (CK-MB): normal 30-170 units/L
*increase 4-6 hrs after MI and remains elevated 24-72hrs
• Troponin normal: <0.2 ng/dL *gold standard for MI
, HCO 3ATI Pharmacology Proctored 2.
- Safe Medication Administration and Error Reduction: Reviewing a Medication
Administration Record (RN QSEN - Teamwork and Collaboration, Active Learning
Template - Nursing Skill, RM Pharm RN 7.0 Ch. 2)
1) Report all errors, and implement corrective measures immediately
2) Complete an incident report within the time frame the facility specifies, usually 24 hr.
3) Do not reference or include this report in the client's medical record
4) Evaluate clients' responses to medications, and document and report them.
5) Identify side and adverse effects, and document and report them.
Chapter 12
- Substance Use Disorders: Therapeutic effect of chlordiazepoxide (Ch. 12 pg.85)
- Substance Use Disorders: Smoking cessation using bupropion (Ch. 12 pg. 87)
- Substance Use Disorders: Treatment for Cocaine Toxicity (Active Learning Template
- System Disorder, RM Pharm RN 7.0 Ch. 12)
1) First line treatment = Benzodiazepines (to reduce CNS & cardiovascular effects)
2) Chlordiazepoxide, diazepam, lorazepam, clorazepate, oxazepam
3) Provide seizure precautions
4) Manifestations include nausea; vomiting; tremors; restlessness and inability to sleep;
depressed mood or irritability; increased heart rate, blood pressure, respiratory rate, and
temperature; diaphoresis; and tonic-clonic seizures. Illusions are also common
5) Monitor vitals and neurological status on a regular basis
Chapter 13
- Chronic Neurologic Disorders: Adverse effects of neostigmine (Ch. 13 pg.
91) Adverse effects:
Excessive muscarinic stimulation
Cholinergic crisis
- Chronic Neurologic Disorders: Medications that interact with Carbamazepine (Ch. 13
pg. 99)
- Carbamazepine causes a decrease in the effects of oral contraceptives and warfarin due to
stimulation of hepatic medication-metabolizing enzymes.
- Grapefruit juice inhibits metabolism, and thus increases carbamazepine levels.
- Phenytoin and phenobarbital decrease effects of carbamazepine.
- Chronic Neurologic Disorders: Adverse Effects of Phenytoin (RN QSEN - Safety,
Active Learning Template - Medication, RM Pharm RN 7.0 Ch. 13)
1) CNS effects: Nystagmus, sedation, ataxia, double vision, cognitive impairment
2) Gingival hyperplasia: Softening and overgrowth of gum tissue, tenderness, and bleeding gums
(consider folic acid supplement)
3) Skin rash (stop medication if rash appears)
4) Cardiovascular effects: dysrhythmias, hypotension (administer slow; 50 mg/min and in dilute
HCO 3ATI
Pharmacology
Proctored 2.
ATI Pharmacology
IMPORTANT LAB VALUES
• Sodium (Na): 136-145 mEq/L
• Calcium: 9.0-10 mg/dL
• Chloride: 98-106 mEq/L
• Bicarb HCO3: 21-28 mEq/L
• Potassium: 3.5-5.0 mg/L
• Phosphorus PO 4 : 3.0-4.5 mg/dL
• Magnesium: 1.3- 2.1 mEq/L
• Cholesterol:
o Total <200mg/dL
o LDL ("bad") <100
o HDL ("good) >40
o Triglycerides <150mg/dL
• Liver enzymes
o ALT/SGPT 8-20 units/L
o AST/SGOT 5-40 units/L
o ALP 42-128 units/L
o Total protein 6-8 gm/dL
• Pancreatic enzymes
o Amylase 56-90 IU/L
o Lipase 0-110 units/L
o Prothrombin time 0.8-1.2
• Glucose:
Preprandial (fasting) 70-110 mg/dL
Postprandial 70-140 mg/dL
• RBC: Females 4.2-5.4 million/uL; Males 4.7-6.1 million /uL
• WBC: 5000 -10,000
• Iron: Females 60-160 mcg/dL; Males 80-180 mcg/dL
• Platelets: 150,000-450,000
• Hemoglobin (Hgb): Females 12-16 g/dL; Males 14-18 g/dL
• Hematocrit (Hct): Females 37-47%;Males 42-52%
• Prothrombin Time (PT): 11-14 seconds: therapeutic range 1.5-2x normal or control
value
• Urine specific gravity: 1.015-1.030
• Urine pH: average 6.0; range 4.6-8.0
• BUN: 10-20 mg/dL
• Creatinine: female 0.5-1.1, males 0.6 - 1.2 mg/dL;
,HCO 3ATI Pharmacology Proctored 2.
• Creatinine phosphokinase MB (CK-MB): normal 30-170 units/L
*increase 4-6 hrs after MI and remains elevated 24-72hrs
• Troponin normal: <0.2 ng/dL *gold standard for MI
, HCO 3ATI Pharmacology Proctored 2.
- Safe Medication Administration and Error Reduction: Reviewing a Medication
Administration Record (RN QSEN - Teamwork and Collaboration, Active Learning
Template - Nursing Skill, RM Pharm RN 7.0 Ch. 2)
1) Report all errors, and implement corrective measures immediately
2) Complete an incident report within the time frame the facility specifies, usually 24 hr.
3) Do not reference or include this report in the client's medical record
4) Evaluate clients' responses to medications, and document and report them.
5) Identify side and adverse effects, and document and report them.
Chapter 12
- Substance Use Disorders: Therapeutic effect of chlordiazepoxide (Ch. 12 pg.85)
- Substance Use Disorders: Smoking cessation using bupropion (Ch. 12 pg. 87)
- Substance Use Disorders: Treatment for Cocaine Toxicity (Active Learning Template
- System Disorder, RM Pharm RN 7.0 Ch. 12)
1) First line treatment = Benzodiazepines (to reduce CNS & cardiovascular effects)
2) Chlordiazepoxide, diazepam, lorazepam, clorazepate, oxazepam
3) Provide seizure precautions
4) Manifestations include nausea; vomiting; tremors; restlessness and inability to sleep;
depressed mood or irritability; increased heart rate, blood pressure, respiratory rate, and
temperature; diaphoresis; and tonic-clonic seizures. Illusions are also common
5) Monitor vitals and neurological status on a regular basis
Chapter 13
- Chronic Neurologic Disorders: Adverse effects of neostigmine (Ch. 13 pg.
91) Adverse effects:
Excessive muscarinic stimulation
Cholinergic crisis
- Chronic Neurologic Disorders: Medications that interact with Carbamazepine (Ch. 13
pg. 99)
- Carbamazepine causes a decrease in the effects of oral contraceptives and warfarin due to
stimulation of hepatic medication-metabolizing enzymes.
- Grapefruit juice inhibits metabolism, and thus increases carbamazepine levels.
- Phenytoin and phenobarbital decrease effects of carbamazepine.
- Chronic Neurologic Disorders: Adverse Effects of Phenytoin (RN QSEN - Safety,
Active Learning Template - Medication, RM Pharm RN 7.0 Ch. 13)
1) CNS effects: Nystagmus, sedation, ataxia, double vision, cognitive impairment
2) Gingival hyperplasia: Softening and overgrowth of gum tissue, tenderness, and bleeding gums
(consider folic acid supplement)
3) Skin rash (stop medication if rash appears)
4) Cardiovascular effects: dysrhythmias, hypotension (administer slow; 50 mg/min and in dilute
